The slight differences between our results and the two other studies might have arisen from technical variation and population-specific effects, as well as the choice of cell type between our study and the BLUEPRPINT study (CD4+ T cells comprising both naïve and memory cells in our sample vs. naïve-only CD4+ T cells in the BLUEPRPINT study) and disease status (MS patients in ours vs. healthy controls in the BLUEPRINT and GOLDN studies). The gene discussed is CD4; the disease is myeloid sarcoma.